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Abstract
Background: It remains unclear into which level the systolic blood pressure (SBP) should be lowered in order to
provide the best cardiovascular protection among older people. Hypertension guidelines recommendation on
attaining SBP levels <150 mmHg in this population is currently based on experts’ opinion. To clarify this issue,
we systematically reviewed and quantified available evidence on the impact of achieving different SBP levels
<150 mmHg on various adverse outcomes in subjects aged ≥60 years old receiving antihypertensive drug
treatment.
Methods: We searched 8 databases to identify randomized controlled trials (RCTs) and post-hoc analyses or
subanalyses of RCTs reporting the effects of attaining different SBP levels <150 mmHg on the risk of stroke, acute
myocardial infarction, heart failure, cardiovascular mortality and all-cause mortality in participants aged ≥60 years.
We performed random-effects meta-analyses stratified by study design.
Results: Eleven studies (> 33,600 participants) were included. Compared with attaining SBP levels ≥140 mmHg,
levels of 130 to <140 mmHg were not associated with lower risk of outcomes in the meta-analysis of RCTs, whereas
there was an associated reduction of cardiovascular mortality (RR 0.72, 95% CI 0.59–0.88) and all-cause mortality
(RR 0.86, 95% CI 0.75–0.99) in the meta-analysis of post-hoc analyses or subanalyses of RCTs. Limited and conflicting
data were available for the SBP levels of <130 mmHg and 140 to <150 mmHg.
Conclusions: Among older people, there is suggestive evidence that achieving SBP levels of 130 to <140 mmHg
is associated with lower risks of cardiovascular and all-cause mortality. Future trials are required to confirm these
findings and to provide additional evidence regarding the <130 and 140 to <150 mmHg SBP levels.
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Background
High blood pressure is one of the leading global risk
factors in terms of cardiovascular disease burden [1–3],
and its impact on mortality rates increases with age [4].
As the process of population aging develops worldwide,
the burden associated with high blood pressure levels is
expected to rise [4].
Antihypertensive drugs reduce cardiovascular events
and all-cause mortality in older people, as demon-
strated by randomized clinical trials (RCTs) comparing
treatment with placebo [5–7]. Because in most of these
RCTs the mean achieved systolic blood pressure (SBP)
in the intervention group was between 140 and 150 mmHg
[5, 6], current guidelines recommend attaining SBP levels
<150 mmHg during antihypertensive drug treatment
among older people [8, 9]. Studies on lower SBP levels
yielded conflicting results regarding cardiovascular protec-
tion [10–13]. Furthermore, older people have a higher risk
of adverse events, particularly concerning kidney failure
and symptomatic hypotension, which may further lead
into falls and fractures [14]. Therefore, based on experts’
opinion, current hypertension guidelines state that indi-
vidual tolerability should be considered when recom-
mending SBP < 140 mmHg [8, 9], and it remains unclear
into which level the SBP should be lowered in order to
provide the best cardiovascular protection without a sig-
nificant increase in serious adverse events in older people.
A comprehensive literature review might help clarify
current evidence on the subject.
We aimed to systematically review and quantify avail-
able evidence on the impact of achieving different SBP
levels <150 mmHg on stroke, acute myocardial infarc-
tion (AMI), heart failure (HF), cardiovascular mortality,
all-cause mortality and adverse events in subjects aged
≥60 years old receiving antihypertensive drug treatment.
Methods
Data sources, search strategy, and eligibility criteria
Eight electronic databases (MEDLINE, EMBASE,
Cochrane library, Web-of-science, Lilacs, Scielo, PubMed
and Google Scholar) were searched from their inception
until July 8th 2016 with no language restriction. Searches
combined terms related to the exposure (e.g., antihyper-
tensive drug treatment), cardiovascular outcomes (e.i,
stroke, AMI, HF, cardiovascular mortality) and all-cause
mortality. We also searched for unpublished studies in
Clinical Trials and European Medical Agency registries
[15–18], asked for experts’ opinion and assessed reference
lists of relevant bibliography (review articles, guidelines
and original studies identified by the electronic searches)
to find other eligible trials. Details of the search strategy
are provided in the Additional file 1 and the accordance
with PRISMA Statement for reporting Systematic Review
and Meta-analysis is described in the Additional file 2.
Inclusion criteria were (i) randomized clinical trials
(RCTs), post-hoc or subanalyses of RCTs (p-h/sa of RCTs);
(ii) assessing the effects of antihypertensive drug treat-
ment; (iii) achieving different SBP levels or a minimum
difference of at least 3 mmHg in SBP between interven-
tion and control groups; and (iv) collecting endpoints for
cardiovascular outcomes and all-cause mortality. The
3 mmHg minimum achieved SBP difference between
intervention and control groups cut-off was chosen based
on previous findings suggesting that a minimum reduction
of 4.6 mmHg in SBP is required to prevent a cardiovascu-
lar event [19]. The lower cut-off (3 mmHg) was chosen to
ensure a conservative approach and has been previously
described [20]. Since we aimed to compare the effects of
antihypertensive drug treatment targeting different SBP
levels, we excluded studies in which all participants on the
control group received placebo only or no treatment. We
also excluded studies in which: (i) antihypertensive drugs
were used for other purposes than lowering blood pres-
sure or in emergency conditions (e.g. angina, arrhythmia,
HF or chronic kidney disease); (ii) both intervention and
control groups achieved a SBP > 150 mmHg; (iii) final SBP
was not described or was not reported for participants
≥60 years old. We followed the 8th Joint age value cut-off
(≥ 60 years old) [9].
All titles, abstracts and full texts were assessed inde-
pendently by two reviewers. Full texts were retrieved for
studies that satisfied all selection criteria.
Data extraction
Two independent authors extracted all relevant data in-
cluding location, study design, baseline characteristics
(mean age, gender, race, hypertension, diabetes, smoking
status and previous cerebrovascular or coronary artery
disease), follow-up time, class of antihypertensive drugs
prescribed, baseline and achieved systolic and diastolic
blood pressure, number of participants and events, all
strokes (fatal and non-fatal), all AMI (fatal and non-fatal),
all HF outcomes (fatal and non-fatal), cardiovascular mor-
tality (according to each study definition), all-cause mor-
tality outcome and adjustments, as well as information on
adverse events. For definition of serious adverse events,
we considered those adverse events classified by the study
as being serious and those defined as kidney failure and
fractures. When data on baseline characteristics or adverse
events were not reported for participants aged ≥60 years
old, we used data from the whole population [13, 21, 22].
When risk estimates were not reported on a RCT, we
calculated relative risk (RR), standard error and 95%
confidence interval (95% CI) [23] on the basis of the
available information from the article [10, 24]. Risk of bias
was assessed using the Cochrane Collaboration’s tool [25]
for RCTs and the Newcastle-Ottawa Scale [26] for p-h/sa
of RCTs.
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Data synthesis and analysis
We classified studies based on the actual cut-offs that
the included studies had used. We considered as inter-
vention and control groups those in which achieved SBP
were, respectively, lower and higher. These criteria
allowed us to compare the following groups: 130 to
<140 versus ≥ 140 mmHg, < 130 versus ≥ 130 mmHg,
and both groups within the range 140 to <150 mmHg.
More detailed information on data synthesis is provided
in Additional file 1.
We performed meta-analysis for each SBP level com-
parison considering RCTs and p-h/sa of RCTs separately
and using random effects model. To be able to perform
sensitivity analyses and to assure quality, results were
pooled when there were at least 3 observations on the out-
come available from studies with moderate to low risk of
bias. Data from outcomes that did not fulfil criteria for
pooling results were reported as part of the systematic re-
view. Hazard ratios were assumed approximate measures
of relative risk. Heterogeneity was assessed using the
Cochrane χ2 statistic and the I2 statistic.
Fixed effect models analyses were conducted as sensi-
tivity analyses and we also provided sensitivity analyses
after exclusion of studies on secondary prevention of
stroke and coronary heart disease [27], after exclusion of
studies in which it was not possible to define whether a
fraction of the participants on the control group re-
ceived only placebo treatment [28], and after exclusion
of studies that included participants aged 60 to <65 years
old [27]. Publication bias was assessed using Begg funnel
plots and the Egger test whenever there were 5 studies
or more available for analysis [29].
Baseline data were analysed as weighted means and
standard deviation for continuous variables and propor-
tions for categorical variables. All statistical tests were
two sided and used a significance level of p < 0.05. We
used Stata release-14 for all statistical analyses.
Results
Study identification and selection
The search strategy identified 11,467 citations. Dataset
search and the assessment of reference lists of relevant
bibliography included 11,464 and 3 citations, respect-
ively. After screening of titles and abstracts, 256 articles
were selected for detailed evaluation of their full text. Of
those, 11 studies met the inclusion criteria and were in-
cluded in the review [10–14, 21, 22, 24, 27, 28, 30]
(Fig. 1). One study provided independent data for two
different age subgroups of participants (65 to 74 and
≥75 years old) [28]. One study compared achieved SBP
levels within the 140 to <150 mmHg range [14], 7 stud-
ies compared the levels 130 to <140 mmHg with
≥140 mmHg [10, 11, 21, 24, 27, 28, 30], and 3 compared
the levels <130 mmHg with ≥130 mmHg [12, 13, 22].
Characteristics of included studies
Table 1 summarizes the characteristics of included studies
and participants. Of the 11 included studies, 4 were RCTs
[10, 11, 13, 24] and 7 p-h/sa of RCTs [12, 14, 21, 22, 27,
28, 30]. More than 33,600 participants (mean age of
72 years old) were followed during a mean of 34 months
across studies (range 9–55 months). Six studies recruited
participants in Europe [12, 14, 22, 27, 28, 30], 4 in
America [12–14, 27] and 6 in Asia [10, 11, 14, 21, 24, 28]
(Table 1e). Four studies described data on race, with the
prevalence of African descendants being <20% in all re-
ports [12, 13, 22, 27]. Eight studies reported data on
stroke [10–14, 21, 24, 27], 7 on AMI [10–14, 24, 27], 4
on HF [10, 13, 24, 27], 10 on cardiovascular mortality
[10–14, 21, 24, 27, 28, 30], 11 on all-cause mortality
[10–14, 21, 22, 24, 27, 28, 30] and 8 on adverse events
in older participants (10–14, 24, 27, 28) (Tables 2 and
2e from Additional file 1). Regarding quality assessment,
Fig. 1 Flow diagram for study selection
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one study was considered to have high risk of bias [30], 6
to have moderate [12, 14, 21, 22, 27, 28], and 4 to have a
low risk of bias [10, 11, 13, 24] (Tables 3e and 4e from
Additional file 1). At baseline, the mean systolic and
diastolic blood pressure of included studies were 158 and
82 mmHg, respectively. The mean achieved systolic and
diastolic blood pressure are reported in each pooled out-
come in Fig. 2.
Cardiovascular outcomes and mortality for achieving SBP
levels 130 to <140 versus ≥140 mmHg
Three RCTs [10, 11, 24] and 3 p-h/sa of RCTs with
moderate or low risk of bias [21, 27, 28], including
24,547 participants, compared cardiovascular and mor-
tality outcomes in older people that achieved SBP levels
130 to <140 with those that achieved SBP levels
≥140 mmHg. In the meta-analysis of RCTs comparing
achieved SBP levels of 130 to <140 mmHg with
≥140 mmHg, the lower levels were not associated with
reductions in the risk of stroke, cardiovascular
mortality or all-cause mortality (Fig. 2). However, in the
meta-analysis of p-h/sa of RCTs, SBP levels 130 to
<140 mmHg were associated with a 28% risk reduction
of cardiovascular mortality and a 14% reduction of all-
cause mortality (Fig. 2).
There was no reduction in the risk of AMI associated
with the 130 to <140 mmHg levels on pooled analysis of
RCTs (Fig. 2) or on the report from one p-h/sa of RCTs
(Table 2) [27]. For the HF outcome, it was not possible to
combine results neither from trials nor from p-h/sa of
RCTs studies because there were less than 3 observations
on the outcome for both study designs. Nevertheless, all
studies that reported results on the outcome found no risk
reduction in HF associated with the SBP levels of 130–
140 mmHg (Table 2) [10, 24, 27].
Cardiovascular and mortality outcomes for achieving SBP
levels within the 140 to <150 mmHg range
One p-h/sa of RCT compared cardiovascular and mor-
tality outcomes in older people that achieved a mean
A B
C D
Fig. 2 Cardiovascular outcomes and all-cause mortality for SBP 130 to <140 versus≥ 140 mmHg. Panel a: stroke; Panel b: acute myocardial
infarction; Panel c: cardiovascular mortality; Panel d: All-cause mortality. Results are stratified by study design. The size of the marker represents
the weight of each trial. Weighted average of blood pressure is described for each outcome. SBP, systolic blood pressure; RR, relative risk; 95% CI,
95% confidence interval; RCTs, randomized controlled trials; D + L, DerSimonian-Laird random effect model
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SBP of 143 mmHg with those that achieved 147 mmHg
[14]. The authors found that the lower level was associ-
ated with mean reductions of 15% in the risk of stroke,
of 28% in the risk of AMI and of 2% in all-cause mortal-
ity, but also with a 5% increase risk in cardiovascular
mortality [14].
Cardiovascular and mortality outcomes for achieving
levels <130 versus ≥130 mmHg
Three studies, including 8834 participants, compared the
SBP levels <130 mmHg with ≥130 mmHg. One study was
a RCT [13] and two were p-h/sa of RCTs [12, 22]. There-
fore, these studies did not fulfil our criteria for combining
their results. The studies that reported on stroke and AMI
outcomes found no reductions associated with the lower
SBP levels (Table 2) [12, 13]. One study that analysed the
HF outcome found a 38% risk reduction associated with
achieving levels <130 mmHg [13]. For the cardiovascular
mortality outcome, there was a tendency towards lower
risk associated with achieving levels <130 mmHg in one
trial [13], and a 61% risk reduction in a post-hoc analysis
[12]. For the all-cause mortality outcome, data were
divergent among the 3 studies. While there was no risk re-
duction detected in one post-hoc analysis [12], another
post-hoc analysis reported a 28% increased risk [22],
whereas the RCT found a 32% lower risk associated with
levels <130 mmHg [13].
Adverse events
Although one of the studies reported an increased risk
of orthostatic hypotension associated with achieving
SBP levels 130 to <140 when compared to ≥140 mmHg
[28], there was no report of consequent increased risk
of fractures [28]. Furthermore, SBP levels130 to
<140 mmHg were not associated with a higher risk of kid-
ney failure or of other serious adverse events (Table 2e
from Additional file 1).
There were no comparisons of adverse events incidence
available for the study in which SBP levels in both inter-
vention and control groups were within the 140 to
<150 mmHg range. Studies comparing SBP levels <130
with ≥130 mmHg found no increased risk of fractures
(Table 2e from Additional file 1) [12, 13]. There was, how-
ever, a higher incidence of emergency visits due to acute
renal failure associated with the SBP levels <130 mmHg
(RR 1.43, CI 95% 1.02–1.99) [31].
Sensitivity analysis and publication bias
In the meta-analyses that compared achieved SBP 130 to
<140 mmHg with ≥140 mmHg, heterogeneity ranged
from low (0.0% in pooled results of RCTs on AMI out-
come) to high (79.3% in the analysis RCTs on all-cause
mortality) (Fig. 2). Due to the limited number of studies,
it was not possible to explore the factors contributing to
the observed heterogeneity. In the sensitivity analysis
using the fixed effect model, we found a significant
reduction in the risk of cardiovascular mortality and all-
cause mortality associated with the 130 to <140 mmHg
level in the combined results of RCTs (Fig. 2). Other
sensitivity analyses yielded results that were not substan-
tially different (Fig. 1e from Additional file 1).
Visual inspection of Begg funnel plots for assessment
of publication bias revealed symmetrical plots and Egger
test estimates were non-significant (p > 0.05) for all ana-
lyses (Fig. 2e from Additional file 1).
Discussion
In this systematic review, we summarized evidence on
achieving SBP levels <150 mmHg in subjects aged
≥60 years old. There was suggestive evidence that achiev-
ing SBP levels of 130 to <140 mmHg is associated with
reductions in the risk of cardiovascular mortality and all-
cause mortality without a subsequent increased risk of
serious adverse events. For SBP levels <130 mmHg, data
on cardiovascular and all-cause mortality prevention are
conflicting, and an increased risk of emergency visits due
to acute kidney failure has been reported [13, 31]. Limited
information on SBP levels within the 140 to <150 mmHg
range impaired conclusions regarding these levels.
In our study, the lower risk of cardiovascular and all-
cause mortality associated with achieving SBP levels of
130 to <140 mmHg found in the meta-analysis of p-h/sa
of RCTs was not supported by the meta-analysis of
RCTs. These divergent results may be a consequence of
differences between studies regarding baseline cardiovas-
cular risk profile of the included participants. The stud-
ies that found no benefits [10, 11] associated with the
130 to <140 mmHg levels included participants that had
a lower baseline cardiovascular risk than those included
in the study that found benefits [24]. Therefore, the
absence of improvements associated with achieving SBP
130 to <140 mmHg found in our meta-analysis of RCTs
could be partially explained by the lower cardiovascular
risk profile of the participants included in these trials.
Furthermore, there was a high proportion of participants
with diabetes or previous coronary heart disease among
those included in the meta-analyses of p-h/sa of RCTs.
These findings endorse the possibility that the benefits
of achieving 130 to <140 mmHg SBP levels might be
restricted to older people with a high cardiovascular risk
profile. Another possible reason for the diverse results is
the difference between studies regarding their number of
events. The two RCTs that found no benefits of lowering
SBP into levels 130 to <140 mmHg had a low number of
strokes, AMI, cardiovascular mortality and all-cause
mortality [10, 11], which may have impaired the power
of the studies to detect a possible benefit associated with
the level. Therefore, the absence of reduction in the risk
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of cardiovascular events and all-cause mortality associ-
ated with the achieved SBP 130 to <140 mmHg found in
our meta-analysis of RCTs may also have been a conse-
quence of the low power of the trials included in the
analyses [10, 11].
The paucity of data on SBP levels within the range
140 to <150 mmHg impaired analyses concerning these
levels. Nevertheless, current evidence suggests that the
SBP level of 143 mmHg might be associated with a re-
duction in the risk of stroke and AMI when compared
to the SBP level of 147 mmHg. Studies reporting on
SBP levels <130 mmHg yielded conflicting results.
While one RCT found a reduction in all-cause mortality
[13], one post-hoc analysis reported no risk reduction
[12] and another study described an increased risk as-
sociated with the level [22]. Similar to the levels 130 to
<140 mmHg, these discrepancies might be explained by
differences between studies regarding baseline cardio-
vascular risk profile of the included participants. The
post-hoc analysis that found a higher risk of all-cause
mortality associated with SBP levels <130 mmHg [22]
had included participants with lower baseline cardio-
vascular risk when compared to the trial that found
benefits [13]. Therefore, the benefits associated with
achieving SBP levels <130 mmHg might be restricted to
older people with a high cardiovascular risk profile. These
assumptions are further supported by recent findings of
HOPE-3 trial [32]. In this RCT, the authors found no ben-
efits of lowering the SBP into levels <130 mmHg on the
composite outcomes of stroke, AMI or cardiovascular
death in older participants with intermediate baseline car-
diovascular risk [32].
In this meta-analysis, we provide data stratified ac-
cording with the range of achieved SBP levels and study
design. In a previous meta-analysis, Xie et al. found that
more intensive BP control reduced the risk of cardio-
vascular events when compared to less intensive con-
trol in participants aged 62 years old or more [33].
However, the authors did not provide clear data on
which achieved BP levels were being analysed in the
more intensive and less intensive groups [33]. Bavishi et
al. meta-analysis of RCTs found that SBP levels
<140 mmHg decreased major adverse cardiovascular
events (MACE) when compared to attaining higher
levels [34]. However, analyses stratified according with
achieved SBP ranges were not provided, therefore, the re-
sults of the study do not clarify whether the decreased
MACE was actually associated with the <130 mmHg SBP
levels [34]. Contradicting these results, Weiss et al. found
no benefits of lowering SBP into levels <140 mmHg when
compared with attaining higher levels [35]. The discrep-
ancy found in their results might be due to the inclusion
of participants receiving only placebo for hypertension
treatment in the control group of studies analysing
achieved SBP levels >140 mmHg [35]. We critically
appraised the literature following an a priori designed
protocol with clearly defined inclusion and exclusion cri-
teria and providing mean BP levels achieved in both inter-
vention and control groups.
Main limitations of the present review are the rela-
tively small number of eligible studies, low number of
incident events and small sample size of some of the
included studies. Because of these limitations, it was not
possible to provide stratified analyses for older ages (e.g.
70 or 80 years old), which would be interesting since the
60 years old cut-off for definition of older people chosen
in this study might be considered too low. However, the
results from our sensitivity analyses on studies including
participants aged ≥65 years old were similar to the re-
sults of the whole study. Furthermore, the mean age of
the participants included in our study was 72 years old,
which meets more strict criteria for definition of the
older population [8]. The small number of studies im-
paired our ability to find which cardiovascular outcome
might be responsible for the reduction in cardiovascular
death, and to provide statistical analyses of potential
sources for the heterogeneity found in our study. Differ-
ences between studies regarding sample sizes, follow-up
period, baseline cardiovascular risk profile, ethnicity and
socioeconomic factors might be explanations for the
heterogeneity found in our meta-analyses. Since older
people are especially susceptible to serious adverse events
associated with antihypertensive drug treatment, a risk-
benefit analysis could provide more information to sup-
port the indication of pharmacotherapy in this population.
Our attempt to provide such risk-benefit analysis was pre-
cluded by the considerable differences between studies re-
garding the definition of serious adverse events.
Future trials providing data on outcomes stratified by
different cardiovascular risk profiles could further identify
which profile benefits best from each SBP level. Moreover,
trials including a larger number of participants and with a
longer follow-up period could correct power issues
observed in previous trials and provide important infor-
mation regarding serious adverse events. Three trials are
currently recruiting participants to analyse the impact of
different SBP levels <150 mmHg in cardiovascular out-
comes [16, 18, 36]. Two will evaluate participants with
previous stroke [16, 18] and one will provide information
for the general population [36]. These studies may help
clarify whether older people with different cardiovascular
risk profile might benefit from different SBP levels.
Conclusions
In this review, we found there is suggestive evidence that
achieving SBP levels 130 to <140 mmHg is associated
with reductions in the risk of cardiovascular and all-
cause mortality without a subsequent increased risk of
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serious adverse events among subjects aged ≥60 years
old. Therefore, we showed that the evidence favoring
this level is stronger than experts’ opinion. Nevertheless,
future trials including a larger number of participants
with different cardiovascular risk profiles and longer
follow-up periods are required to confirm these findings,
to clarify which cardiovascular events might be pre-
vented when the level 130 to <140 mmHg is achieved
and to provide additional evidence regarding the <130
and 140 to <150 mmHg SBP levels.
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